Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1983 1
1987 1
1996 4
1997 2
1998 1
1999 2
2012 1
2014 1
2016 1
2017 2
2018 2
2019 3
2020 3
2021 6
2022 6
2023 5
2024 6
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, Büttner T, Hahn O, Grünwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zschäbitz S, Schwab C, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, Hölzel M, Eckstein M. Klümper N, et al. Among authors: erne e. Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764. Clin Cancer Res. 2023. PMID: 36534531 Free PMC article.
Autoantibodies neutralizing type I IFNs underlie severe tick-borne encephalitis in ∼10% of patients.
Gervais A, Marchal A, Fortova A, Berankova M, Krbkova L, Pychova M, Salat J, Zhao S, Kerrouche N, Le Voyer T, Stiasny K, Raffl S, Schieber Pachart A, Fafi-Kremer S, Gravier S, Robbiani DF, Abel L, MacDonald MR, Rice CM, Weissmann G, Kamal Eldin T, Robatscher E, Erne EM, Pagani E, Borghesi A, Puel A, Bastard P, Velay A, Martinot M, Hansmann Y, Aberle JH, Ruzek D, Cobat A, Zhang SY, Casanova JL. Gervais A, et al. Among authors: erne em. J Exp Med. 2024 Oct 7;221(10):e20240637. doi: 10.1084/jem.20240637. Epub 2024 Sep 24. J Exp Med. 2024. PMID: 39316018 Free PMC article.
[Active surveillance in prostate cancer].
Erne E, Kaufmann S, Nikolaou K, Stenzl A, Bedke J. Erne E, et al. Urologe A. 2019 May;58(5):511-517. doi: 10.1007/s00120-019-0921-6. Urologe A. 2019. PMID: 31016332 Review. German.
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Perrone F, et al. J Transl Med. 2020 Oct 21;18(1):405. doi: 10.1186/s12967-020-02573-9. J Transl Med. 2020. PMID: 33087150 Free PMC article. Clinical Trial.
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Perrone F, et al. J Transl Med. 2021 Oct 21;19(1):442. doi: 10.1186/s12967-021-03094-9. J Transl Med. 2021. PMID: 34674735 Free PMC article. No abstract available.
[Rational follow-up of non-muscle invasive bladder cancer].
von Landenberg N, Benderska-Söder N, Bismarck E, Kernig K, Erne E, Goebell PJ, Schmitz-Dräger BJ. von Landenberg N, et al. Among authors: erne e. Urologe A. 2021 Nov;60(11):1409-1415. doi: 10.1007/s00120-021-01683-6. Epub 2021 Oct 15. Urologe A. 2021. PMID: 34652477 Review. German.
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data.
Piselli P, Tavelli A, Cimaglia C, Muccini C, Bandera A, Marchetti GC, Torti C, Mazzotta V, Pipitò L, Caioli A, Girardi E, Antinori A, Serraino D, d'Arminio Monforte A, Cingolani A; Icona Foundation Study Group. Piselli P, et al. Int J Cancer. 2025 Sep 15;157(6):1142-1153. doi: 10.1002/ijc.35493. Epub 2025 May 29. Int J Cancer. 2025. PMID: 40437996 Free PMC article.
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort.
Gagliardini R, De Benedittis S, Tavelli A, Lapadula G, Mazzotta V, Bruzzesi E, Cervo A, Carrozzo G, Saracino A, Rusconi S, Marchetti G, Ceccherini-Silberstein F, Antinori A, d'Arminio Monforte A, Muccini C; Icona Foundation Study Group. Gagliardini R, et al. J Antimicrob Chemother. 2025 Aug 1;80(8):2169-2178. doi: 10.1093/jac/dkaf184. J Antimicrob Chemother. 2025. PMID: 40570134 Free PMC article.
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation.
Mussini C, Giacomelli A, Quiros-Roldan E, Mazzotta V, Di Biagio A, De Vito A, Costantini A, D'Ettorre G, Giacometti A, Vergori A, Tavelli A, Malagnino V, Castagna A, Chester J, Antinori A, d'Arminio Monforte A, Cozzi-Lepri A; Icona Foundation Cohort Study for the Icona Foundation Study Group. Mussini C, et al. EClinicalMedicine. 2025 Jul 24;86:103368. doi: 10.1016/j.eclinm.2025.103368. eCollection 2025 Aug. EClinicalMedicine. 2025. PMID: 40740293 Free PMC article.
Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk Bladder Cancer.
Schmitz-Dräger BJ, Bismarck E, Roghmann F, von Landenberg N, Noldus J, Jahn D, Kernig K, Hakenberg OW, Goebell PJ, Hennenlotter J, Erne E, Stenzl A, Rowinski M, Schiffhorst G, Baranek T, Benderska-Söder N. Schmitz-Dräger BJ, et al. Among authors: erne e. Eur Urol Oncol. 2025 Aug;8(4):1041-1049. doi: 10.1016/j.euo.2025.04.020. Epub 2025 May 7. Eur Urol Oncol. 2025. PMID: 40340174 Clinical Trial.
54 results